Opdivo and Hepatitis aggravated - a phase IV clinical study of FDA data

Summary:

Hepatitis aggravated is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Yervoy, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Hepatitis aggravated when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Hepatitis aggravated?

Hepatitis aggravated is found to be associated with 1,157 drugs and 433 conditions by eHealthMe. Check the latest studies of Hepatitis aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 430 people (0.76%) have Hepatitis aggravated.

Could Opdivo cause Hepatitis aggravated?

Among these 430 people:

How long have people been on Opdivo when they have Hepatitis aggravated? *

Click here to view more results

What is the gender of people who have Hepatitis aggravated when taking Opdivo? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Hepatitis aggravated?

- Check whether Hepatitis aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Hepatitis aggravated treatments and more:

Hepatitis aggravated (33 reports)

How severe was Hepatitis aggravated and when was it recovered:

Hepatitis aggravated in Opdivo

Expand to all the drugs that have ingredients of nivolumab:

Hepatitis aggravated and drugs with ingredients of nivolumab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis aggravated:

Hepatitis aggravated (1,157 drugs)

Browse all the conditions that are associated with Hepatitis aggravated:

Hepatitis aggravated (433 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.